Welcome to RadioGel®

Y-90 RadioGel™ is a device designed for radiation treatment of solid tumors. The Y-90 RadioGel™/Hydrogel mixture is injected directly and uniformly into tumors.

Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

Also known as PRnT™, the treatment uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area, delivering therapeutic radiation from within the tumor. 

We are a team dedicated to developing a safer, less invasive cancer treatment for humans and animals worldwide.

Click the link for the latest press releases

RadioGel is a division of Vivos Inc.

"RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only."